18F-FDG PET-CT Findings Before and After Laparoscopic  Cryoablation of Small Renal Mass:  An Initial Report by Lagerveld, Brunolf Walther et al.
Journal of Kidney Cancer and VHL 2015; 2(4):174-186.        http://jkcvhl.com  
 
Journal of Kidney Cancer and VHL 2015; 2(4):174-186 
DOI: http://dx.doi.org/10.15586/jkcvhl.2015.42 
 
 
Original Article 
 
18F-FDG PET-CT Findings Before and After 
Laparoscopic Cryoablation of Small Renal Mass:  
An Initial Report 
 
Brunolf W. Lagerveld,1 Ferida Sivro,2 Johan A. van der Zee,1  
Phillippe C. Baars2 
 
1Department of Urology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; 2Department of 
Nuclear Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 
 
Abstract 
 
The aim of this study was to describe the characteristics of positron emission tomography 
(PET) molecular imaging combined with low-dose computed tomography (CT) in small renal 
mass (SRM) treated with cryoablation (CA). Currently, treatment success is defined by the 
absence of contrast enhancement at CT. However, the use of contrast is relatively 
contraindicated in patients with renal function impairment, mandating alternative follow-up 
strategies. Several reasons were identified as criteria for performing PET-CT before and/or 
after SRM-CA in 9 patients, and the results were retrospectively studied. The histology 
revealed renal cell carcinoma in 7 patients and oncocytoma in 2 patients. In 6 patients, a 
PET-CT was performed before and after CA. In one patient, the PET-CT was performed only 
before CA and in 2 patients only after CA. Before CA, clearly there was metabolic uptake of 
fluorine-18 fluorodeoxyglucose (18F-FDG) in the SRM in all patients. Following CA, the 
absence of 18F-FDG uptakes in the SRM could clearly be noticed. However, the tracer 
cannot always be distinguished from focal recurrence or reactive inflammatory tissue. In 
one patient, asymptomatic metastatic bone lesions were noticed when performing PET-CT 
at follow-up. This pilot study with 18F-FDG PET-CT for the follow-up of SRM cryosurgery 
showed that 18F-FDG PET-CT imaging could be used to characterize cryoablative tissue 
injury at different times after CA. 
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Introduction 
 
The number of new renal cancer cases in 
the Netherlands was estimated to be 2000 
in the year 2007 and is expected to 
increase to 2300 new cases by the year 
2020. This increase may be due in part to 
an increase in the discovery of small 
incidental solid renal masses (RMs) using 
cross-sectional imaging (1). Recommended 
by principal guidelines, nephron-sparing 
procedures for the management of small 
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RMs have become the standard. Recently, 
cryoablation (CA) has been added as a 
viable treatment option for patients with 
small RM and for those who are at high 
surgical risk (2-4). Patients who can 
particularly benefit from thermal ablation 
procedures are those who are poor surgical 
candidates because of compromised renal 
function and/or comorbid disease. 
However, patients with impaired renal 
function who are candidates for ablation 
can be poor subjects for the typical 
investigational methods used at follow-up. 
 
According to principal guidelines, in 
practice, there is no consensus on which 
the set of diagnostic tools, time frame, and 
frequency of follow-up of the RM-CA are 
recommended (2, 3). Vascular damage and 
consequently ischemic injury is one of the 
mechanisms of action in CA (5). The 
mainstay of follow-up is the assessment of 
perfusion in and around the ablated area. 
Therefore, the current recommendation for 
follow-up of RM-CA is based on imaging of 
blood flow. The imaging method selected 
should be able to evaluate the presence or 
absence of vital tissue in the ablated area 
and measure the size of the lesion. 
Routinely, contrast-enhanced computed 
tomography (CT) or magnetic resonance 
imaging (MRI) is used (6). Intravenously 
administered contrast agents are used to 
identify contrast enhancement in the target 
lesion. The observation that the standard 
follow-up of cryoablated RM in patients 
with declined renal function is not without 
the risk of jeopardizing the remaining renal 
function led to the study of alternative 
methods of follow-up. The development of 
contrast-induced nephropathy is a 
significant complication of intravascular 
contrast-medium use that is related to 
excess morbidity and mortality (7, 8). The 
most important risk factor is preexisting 
renal impairment that increases the risk of 
contrast-induced nephropathy by more 
than 20 times (9). Therefore, alternative 
imaging, not requiring radiographic 
contrast medium, should be considered if 
the alternative imaging adequately 
addresses the diagnostic questions. 
 
Alternative methods of imaging can focus 
either on the vascular or on the molecular 
changes in the CA zone. A method for 
studying the molecular status of RMs is the 
positron emission tomography (PET) in 
combination with low-dose CT, which 
assesses both RM anatomy and metabolic 
activity. Fluorine-18 fluorodeoxyglucose 
(18F-FDG) is the most frequently used 
radiopharmaceutical tracer in PET-CT 
imaging. However, it is not very accurate in 
distinguishing renal cell carcinoma (RCC) 
from the benign solid renal neoplasm. 
Relatively differentiated cancers such as 
RCC show faint or no 18F-FDG uptake that 
consequently results in negative PET-CT 
scans. As a result, 18F-FDG is not routinely 
used in the initial diagnostic workup of 
solid RM (10). There are nuclear tracers that 
better distinguish for RCC, but the 
availability is limited by their short half-life 
(11, 12). However, 18F-FDG PET-CT can 
possibly be a reasonable alternative to the 
routine mode of imaging in those patients 
with relative or imperative contraindications 
for the use of contrast agents in CT or MRI. 
This factor makes 18F-FDG PET-CT of 
interest for the follow-up of CA tumors. The 
hypothesis of this study was that if 18F-
FDG metabolism could be detected in RM 
before CA, it should not be detectable in 
the target zone after CA. The purpose of 
this study was to describe the spectrum of 
pre- and postablation 18F-FDG PET-CT 
findings and define their value during 
follow-up for RM treated with cryosurgery. 
 
Materials and methods 
 
A total of 9 patients treated with 
cryosurgery between July 2007 and 
January 2012 were investigated. All 
patients were identified with an RM 
suspected for malignancy. According to the 
guidelines, patients were informed about 
optional treatment techniques and each 
typical follow-up method. All patients 
consented for CA. The same surgeon 
performed all laparoscopic CA (LCA) or 
percutaneously CT-guided procedures. For 
CA, multiple 17-gauge cryoprobes (Galil 
Medical, Yokneam, Israel) were used. 
Histological biopsies were obtained before 
CA or intraoperatively. 
 
Several reasons were identified as inclusion 
criteria to prefer PET-CT instead of CT or 
MRI: renal function impairment, contrast 
allergy, contraindication for the use of 
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Table 1. Patient characteristics and demographics 
 
Study 
number 
Age at 
time of 
CA 
(years) 
Gender Tumor 
size 
(mm) 
Histology GFR-
MDRD 
Solitary 
kidney 
1 76 M 45 Clear cell RCC 31 No 
2 80 M 44 Clear cell RCC 32 Yes 
3 72 M 19 Clear cell RCC 55 Yes 
4 68 M 36 Clear cell RCC 61 No 
5 64 F 30 Chromophobe 
RCC 
52 Yes 
6 79 M 40 Clear cell RCC 65 No 
7 64 M 43 Clear cell RCC 33 No 
8 70 M 38 Oncocytoma 99 No 
9 75 M 48 Oncocytoma 21 No 
CA=cryoablation; RCC=renal cell carcinoma; GFR-MDRD=glomerular filtration rate-modification of 
diet in renal disease. 
 
intravenous contrast medium, 
claustrophobia, metal implants, PET-CT 
already performed in a referring center, 
staging of renal cancer, and the 
identification of a viable tissue metabolism 
in the case of suspected local recurrence of 
renal cancer after initial ablative treatment. 
 
Those patients who underwent 18F-FDG 
PET-CT before and/or after RM-CA were 
retrospectively studied. Patients were 
identified in our institutional database. The 
local internal review board approved this 
study. 
 
PET-CT technique 
 
18F-FDG is a glucose analogue with a 
positron-emitting 18F radioactive isotope 
substituted for the hydroxyl group at the 
second position in the glucose molecule. 
PET imaging of tumors with the FDG tracer 
is based on the observation that the tumor 
cells have an enhanced rate of glycolysis 
compared to the most normal tissue. The 
uptake of glucose and analogue FDG into 
malignant cells is facilitated by the 
increased expression of glucose transporter 
molecules at the tumor cell surface (13). 
After intracellular transport, FDG is 
phosphorylated by hexokinase to FDG-6-
phosphate, does not proceed further in the 
metabolic pathway, and remains trapped in 
cells. PET identifies this selective focal 
accumulation of positron-emitting FDG in 
malignant tumors. The glucose metabolic 
status can be analyzed quantitatively as 
the differential uptake ratio and 
distribution absorption ratio known as the 
standardized uptake value (SUV) index. 
 
Patients with renal function impairment 
(GFR-MDRD <60 ml/min/1.73 m2) before 
LCA treatment were offered 18F-FDG PET-
CT imaging. In case the target lesion 
showed metabolic activity before CA, the 
PET-CT was repeated after LCA to assess 
therapy success. It was postulated that 
shortly following ablation zone metabolic 
activity was to be expected at 18F-FDG PET-
CT within and around the ablation. This 
would make it difficult to discriminate 
between inflammatory/reactive tissue and 
viable tumor tissue. Therefore, the first 
post-CA PET-CT imaging was performed 
with a minimum of 3 months following 
surgery. 
 
According to the local protocol, the 
treatment success of CA is determined the 
first time postoperative contrast-enhanced 
CT imaging is performed and is defined by 
the absence of (focal) enhancement within 
the ablated tumor area (14). However, 
under the circumstances of case-specific 
indications and awareness of preoperative 
PET-CT findings, a postoperative contrast-
enhanced CT or MRI was not performed in 
all cases. In several cases, the PET-CT was 
combined with abdominal ultrasonography. 
Blood glucose level was measured prior to 
administering FDG. The plasma glucose 
level was used to correct SUV 
measurements. A bolus of 18F-FDG (range 
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Table 2. In 6 patients, 18F-FDG PET-CT imaging was performed before and after 
cryoablation (CA) 
 
Patient number SUV renal mass 
center 
SUV renal mass 
periphery 
SUV liver 
2a 1.8 1.7 2.6 
2b 0.8 3.1 2.4 
2c 0.7 3.1 2.6 
3a 3.2 2.8 2.8 
3b 3.2 2.6 3.2 
4a 3.9 3.3 3.2 
4b 1.5 2.2 3.0 
4c 0.6 0.9 2.3 
4d 0.6 0.9 2.7 
4e 0.7 0.7 3.2 
5a 1.95 1.95 2.95 
5b 1.4 2.9 3.2 
5c 1.4 2.1 3.0 
7a 2.5 2.6 2.8 
7b 1.5 2.7 3.2 
7c 1.5 2.9 3.4 
9a 3.1 3.5 3.7 
9b 1.0-1.5 4.5-4.7 3.0 
SUV scores are detailed for before CA (a), at first time follow-up (b), and consecutive (c, d, e) follow-up. 
 
141-233 MBq) was intravenously 
administered 60-90 minutes prior to 
imaging. A PET scan was performed from 
the skull base to the groin and combined 
with a low-dose CT for attenuation 
correction and anatomic correlation. At 
preoperative PET-CT imaging, the metabolic 
uptake was measured in the center of the 
tumor and the liver for reference. At 
postoperative PET-CT, the metabolic uptake 
was calculated in the tumor center, the 
peripheral rim of the tumor, suspect lesions, 
and the liver for reference. 
 
Results 
 
General results 
 
A total of 9 patients treated with 
cryosurgery, between July 2007 and 
January 2012, were retrospectively studied 
in case preoperative workup and/or follow-
up consisted of an 18F-FDG PET-CT. Patient 
characteristics and general surgical 
information of this study are detailed in 
Table 1. Of the 9 primary tumors that were 
treated with CA, 7 were diagnosed 
histologically as malignant and 2 as benign. 
 
Indications for PET-CT before and/or after 
LCA were renal function impairment (n=6), 
suspicion for local recurrence following 
LCA (n=1), and contraindication for 
intravenous contrast-medium use (n=1), 
and in one patient, a preoperative PET-CT 
was performed at the referring center for 
staging purposes. 
 
Before CA, there was clearly metabolic 
uptake of 18F-FDG in the renal tumor in all 
patients (n=8). In this series, we performed 
a PET-CT before and after ablative surgery 
in 6 cases (Table 2). It was noticed that the 
metabolic uptake of 18F-FDG can be 
detected in solid renal lesions, and 
therefore, this could be used as a reference 
to discriminate for metabolic activity after 
RM-CA. In all those cases, we found a 
significant decrease of metabolic FDG 
uptake in the center of the cryoablated 
tumors. However, in the surrounding rim of 
the ablation area in some patients, clear 
absence of the 18F-FDG tracer could not 
always be distinguished from focal 
recurrence or reactive inflammatory tissue. 
 
Case reports 
 
Because of the decline in renal function in 
patient number 1, PET-CT was offered as 
the method of imaging at initial follow-up. 
There was no baseline preoperative PET-CT 
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Figure 1. Patient number 2, an example of 18F-FDG-distribution in a renal mass before (A) and after 5 
months cryoablation (B) at PET-CT. The light active hypointense uptake in the tumor in the left 
kidney before cryoablation (green arrow panel A) has changed to a hypometabolic area after ablation 
(green arrow panel B). The activity around the ablated tumor in the perirenal fat is possibly due to 
inflammatory tissue reaction. A contrast-enhanced CT scan as a control showed no enhancement of 
the ablation zone after treatment. 
 
scan performed for comparison. The follow-
up PET-CT at 10 months showed no 
metabolic activity in the center of the 
ablation zone. However, there was some 
uptake of FDG around the border of the 
initial tumor. This could be due to reactive 
inflammation or rest of tumor activity. The 
test was not conclusive in view of the 
absence of a baseline PET-CT. The patient 
did have consecutive PET-CT imaging at 2 
and 3 years follow-up. Both scans reported 
no evidence of tumor activity in the 
ablation zone. The activity as noticed at the 
first post-CA PET-CT was no longer visible. 
The low-dose CT scans showed a decrease 
in the size of the ablated tumor. In this 
case, there was no contrast-enhanced CT 
or MR scan performed as a control study. 
At 67 months follow-up, no recurrence or 
new RM was found using ultrasonography. 
 
In patient number 2, the renal function 
impairment was the reason for a PET-CT 
scan prior to ablative surgery. Medical 
history revealed a right radical nephrectomy 
for RCC. Hypointense (compared to the liver) 
FDG uptake was noticed in the RM center 
(Figure 1A). Contrast-enhanced CT at 1 
month after CA showed a complete ablation 
of the tumor with some inflammatory 
reactive tissue in the perirenal fat. Five 
months post-CA, the PET-CT showed no 
metabolic activity in the ablation zone. 
However, some activity was noticed in the 
perirenal fat covering the outer border of the 
ablated tumor (SUV 3.1). This activity could 
be due to reaction or inflammation 
(Figure 1B). A PET-CT scan, performed at 
13 months follow-up, again showed no 
metabolic activity in the ablation zone and 
again a slight FDG uptake was noticed in 
the perirenal fat covering the outer border of 
the ablated tumor. At 40 months follow-up, 
there was no sign of recurrence as reported 
by the referring urological center. 
 
The medical history of patient number 3 
revealed a radical nephrectomy for RCC 
and transurethral resection of single 
metachronous metastasis in the bladder. 
Follow-up contrast-enhanced CT scan 
showed an enhancing RM in the solitary 
kidney. The pre-CA PET-CT showed 
metabolic FDG uptake in the lesion. During 
the follow-up PET-CT, 3 months after LCA, 
there still was an irregular FDG uptake 
noticed in the ablated tumor. However, the 
contrast-enhanced CT at 6 months after 
LCA showed a completely ablated tumor 
without contrast enhancement. No biopsy 
was performed to assess recurrence. At 1 
year follow-up, there was no evidence of 
vital RCC at contrast-enhanced CT. Shortly 
thereafter, the patient was diagnosed with 
castration-resistant metastatic prostate 
cancer resulting in his death. 
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Figure 2. Consecutive 18F-FDG PET-CT imaging of a renal cancer before and after cryoablation: Green 
arrows indicate the tumor or the ablation site in the left kidney of patient number 4. Before surgery, 
(A) there was metabolic activity noticed in the tumor. The low-dose CT scans showed consecutive 
decrease in the tumor volume, and no metabolic activity was measured in the tumor using 18F-FDG 
PET at 5 months (B), 15 months (C), and 24 months (D) follow-up after LCA. However, at 34 months, 
newly developed metabolic activity was noticed in the perirenal fat that covered the ablated tumor 
(green arrow panel E). Spontaneous disappearance of metabolic activity in the perirenal fat at 63 
months (panel F). 
 
Because there was suspicion for 
macroglobulinemia in patient number 4, 
there was a contraindication for 
intravenous contrast-medium usage. The 
pre-CA PET-CT showed FDG uptake in the 
RM (Figure 2A). After LCA, the suspicion of 
macroglobulinemia was not proven and a 
contrast-enhanced CT was performed, 
which showed complete ablation of the 
tumor. Five months after LCA, the PET-CT 
revealed no FDG uptake in the ablated 
tumor as shown in Figure 2B. Also at 15 
and 24 months follow-up, the PET-CT 
scans showed no sign of recurrence (Figure 
2C and D). However, at 34 months follow-
up, the PET-CT revealed FDG uptake at the 
dorsolateral side of the left kidney in the 
perirenal fat that covered the ablation area 
(Figure 2E). This uptake was considered 
suspicious for RCC recurrence, and 
contrast-enhanced CT confirmed the 
diagnosis. However, the patient refused 
biopsy or retreatment. Contrast-enhanced 
CT at 40 months follow-up revealed the 
same enhancing tissue in the perirenal fat. 
However, no other suspicious lesions and 
no enhancement of the ablated zone were 
found. The suspected lesion did not 
increase in size. At repeat contrast-
enhanced CT at 47 months follow-up, this 
lesion had almost disappeared. The follow-
up PET-CT scans at 54, 63, and 72 months 
showed a complete disappearance of FDG 
uptake in the ablated area, as well as in 
the perirenal fat covering the ablated zone. 
 
Patient number 5, with a nephrectomy for 
RCC in the past, was diagnosed with a 
suspected malignancy in the solitary 
kidney. The pre-CA PET-CT revealed a 
tumor with low FDG uptake. Following CA 
at 7 months, there was no accumulation of 
FDG in the ablated tumor. The border of 
the ablation site showed some metabolic 
activity that was not suspected to be focal 
recurrence. The consecutive PET-CT at 16 
months follow-up again revealed no 
metabolic activity in the ablated tumor. 
Additionally, a renal ultrasound was 
performed, which showed a decrease in the 
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Figure 3. Imaging at 15 months follow-up of patient number 5. A, Intravenous contrast-enhanced CT 
scan in patient number 5 showing a non-enhancing zone (white arrow) at the side of the renal lesion 
treated with LCA. A second solid lesion with clear contrast enhancement (red arrow) was noticed. B, 
At 18F-FDG PET-CT, the ablation zone showed no metabolic FDG uptake (white arrow). The blue 
arrow indicates the region of the metachronous RCC with FDG uptake (SUV 3.1). 
 
size of the ablated tumor. However, there 
was suspicion of a new RM superior from 
the ablation zone. At control contrast-
enhanced CT, there was no enhancement 
of the ablated tumor. However, near the 
abated tumor, a new contrast-enhanced 
RM was noticed (Figure 3A), confirming 
the findings using ultrasound. It was 
considered a metachronous metastasis and 
not an evidence for focal recurrence after 
LCA. This tumor was almost completely 
endophytic and initially not recognized at 
follow-up PET-CT. The patient underwent a 
successful CT-guided percutaneous CA for 
this second lesion. The histology confirmed 
RCC. At 15 months following the second 
CA, 2 new metachronous lesions were 
diagnosed at contrast-enhanced CT and 
successfully treated with angio-beam-CT-
assisted percutaneous CA. 
 
There was no PET-CT performed prior to 
LCA in patient number 6. The first follow-up 
contrast-enhanced CT at 3 weeks after LCA 
showed complete ablation of the tumor. 
However, the consecutive scan at 7 months 
showed new focal enhancement in the 
dorso-central rim of the initially CA tumor 
suspected for recurrence (Figure 4A). At 
PET-CT, the center part of the tumor 
showed no FDG uptake (SUV 1.2-1.5) 
compared to the liver as reference (SUV 2.8). 
However, the dorso-central area of the initial 
ablated tumor showed metabolic activity 
(SUV 2.7-2.8). This FDG uptake could be 
related to an inflammatory reaction, focal 
recurrence, or the accumulation of FDG in 
the collecting system (Figure 4B). The 
finding of focal enhancement at the 
contrast-enhanced CT was decisive for 
offering consecutive treatment. This 
recurrence was successfully treated with 
CT-guided percutaneous CA. Histological 
biopsy revealed recurrence of vital RCC 
tissue. Follow-up with contrast-enhanced 
CT up to 43 months after the retreatment 
still shows no signs of recurrence. 
 
Patient number 7 was offered a PET-CT 
because of poor renal function before 
treatment of a suspected RM. At the center 
of this tumor, a low FDG uptake was found 
at the pre-CA PET-CT (Figure 5A). The 
patient underwent LCA via a 
retroperitoneal approach. At contrast-
enhanced CT, performed 2 weeks following 
surgery, the tumor showed consistent 
enhancement of the superior-anterior part 
that was considered an incomplete ablation 
with persistent vital tumor as a result. 
Consequently, the LCA was repeated by 
intraperitoneal approach. The PET-CT at 6 
months post-LCA showed the now 2 times 
CA RM without clues for vital tumor tissue 
(Figure 5B). However, now there were 2 
FDG-avid bone localizations that were 
strongly suspected to be osteolytic 
metastases as is shown in Figure 6. The 
contrast-enhanced CT as control and for 
further dissemination study showed no 
particular enhancement of the ablated 
tumor. The bone metastases were treated 
with external beam radiation. During the 
follow-up, pulmonary metastases also 
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Figure 4. Local RCC recurrence of RM-CA. At 8 months following LCA for patient number 6, a focal 
contrast-enhanced area at the posterior side within the ablation zone was noticed on contrast-
enhanced CT scan (A, blue arrow). Although not as sharply distinctive as the contrast-enhanced CT 
scan, we noticed metabolic activation in the same posterior rim area at 18F-FDG PET-CT scan 
(B, blue arrow). 
 
developed, and palliative systemic 
treatment was administered. The patient 
died 2 years later of systemic disease. 
 
Patient number 8 was referred for LCA 
treatment of an incidentally discovered RM 
in the left kidney. The referring center 
performed an 18F-FDG PET-CT for 
dissemination purposes and showed a 
metabolically active (SUV 5.7) tumor of the 
left kidney. The patient underwent LCA. 
The histology obtained by intraoperative 
biopsies revealed oncocytoma. Because of 
the benign nature of this RM, no 
postoperative PET-CT was performed. The 
postoperative contrast-enhanced CT 
showed a complete ablation of the RM. 
 
Patient number 9 was offered PET-CT prior 
to LCA because of poor renal function. In 
case of proven malignancy, we could offer 
follow-up using PET-CT. At pre-CA PET-CT, 
there was FDG uptake in the tumor located 
in the left kidney. Even though the 
intraoperative biopsies revealed a histological 
diagnosis of oncocytoma, the patient was 
offered a PET-CT to define treatment success. 
After CA, in comparison with the PET-CT 
before CA, there was a change in the image 
of the tumor in the left kidney, with a 
recognizable pattern of isometabolic to no 
metabolic activity. There was no contrast-
enhanced CT performed as control. 
Discussion 
 
In 2005, the first report of using fused 
PET-CT imaging for the follow-up of an RM 
treated with CA was published (15). This 
case report showed that a decrease of 
molecular activity was found using PET-CT 
in the RM after cryosurgery compared to 
that using PET-CT before surgery. The 
purpose of this study was to determine 
whether tracer uptakes found at baseline 
and no tracer uptake at follow-up in 18F-
FDG PET-CT could be used to assess the 
response to CA for RCC. We noticed that 
solid tumors could be detected as 
metabolically active lesions at 18F-FDG 
PET-CT imaging. However, the 18F-FDG 
PET-CT is not routinely used in the initial 
diagnostic workup of solid RM because it 
does not discriminate between benign and 
malignant renal growth (10). Hence, this 
study showed metabolic activity in 
oncocytoma and RCC. The number of cases 
was too limited to be able to assess a 
possible difference in the SUV for benign 
and malignant RM. However, this study 
showed that 18F-FDG uptake can be 
detected in solid renal lesions. Therefore, 
this could be used as a reference to 
discriminate for metabolic activity after 
RM-CA. In all those cases, we found a 
significant decrease of metabolic FDG 
uptake in the center of the CA tumors. 
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Figure 5. FDG patterns before and after RM-CA in patient number 7. Before treatment (A), the renal 
tumor in the right kidney shows a low FDG uptake at 18F-FDG PET-CT. The PET-CT scan after 
treatment (B) shows the same tumor without signs of the existence of vital tissue. Green arrows 
indicate the tumor before (A) and after (B) cryoablation. 
 
Therefore, we postulate that 18F-FDG PET-
CT imaging can be used as an alternative 
imaging method to contrast-enhanced 
CT/MRI for the assessment of treatment 
success of LCA. 
 
In all cases, there was a relative or 
imperative reason for the use of an 
alternative imaging technique other than 
intravenous contrast-medium imaging to 
assess the renal tumor viability before and 
after CA. One of the major benefits of 18F-
FDG PET-CT is that there are no 
contraindications for patients with 
decreased renal function. The patient’s 
height, body weight, and medical history 
of diabetes mellitus are essential for the 
interpretation of SUV measurements (16). 
FDG-PET and CT are imaging modalities 
that have been validated in routine clinical 
practice. Integrated PET/CT combines PET 
and CT in a single imaging device and 
allows morphological and functional 
imaging to be carried out in a single 
procedure. This integration has 
advantages for the assessment of the 
vitality of a small RM before and after CA. 
Vascular damage and consequently 
ischemic injury is a significant mechanism 
of action in CA (5). The current mainstay 
of follow-up is the assessment of vascular 
flow in and around the ablated area. 
Therefore, the recommendations for 
follow-up of CA for a small renal tumor are 
based on imaging of blood flow (14). 
However, identifying the absence of 
metabolic activity using PET can also 
assess the viability of tissue. Another 
morphological feature is that CA renal 
tumors tend to decrease in size over time. 
At 3 years of follow-up of patients treated 
with LCA, Gill et al. (17) observed a 
gradual involution of the ablation zone 
diameter by an average of 75%. 
Furthermore, 38% of the ablation zones 
were undetectable on MRI after 3 years 
follow-up. Even though low-dose non-
contrast-enhanced CT is not intended for 
radiological diagnosis, it makes it possible 
to see a decrease in the size of most 
ablated tumors over time. 
 
One of the limitations of this study was the 
resolution achieved by PET-CT. It does not 
allow for accurate interpretation of metabolic 
activity at the rim borders of the ablation 
zone. The measurement of SUV in an area 
selected <1 cm diameter becomes inaccurate 
and, therefore, selection of the region of 
interest is of utmost importance. However, at 
a short distance, a focal recurrence can be 
surrounded by FDG concentrating 
morphological structures, such as the 
normal renal parenchyma and/or the 
urinary collecting system. Artifacts as a 
result of high FDG concentration in the urine 
can be minimized by adequate prehydration. 
In patient number 6, FDG accumulation was 
found in the rim of the ablation zone at the 
dorso-central border. Initially, this was not 
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Figure 6. Panel of 18F-FDG PET-CT imaging at 6 months follow-up of patient 7. There are 2 FDG-avid 
bone localizations strongly suspected of being metastases (A, B). The low-dose CT scan without 
contrast shows cystic lesions in the right iliac bone (A, green circle) and in the fifth left costal rib 
(C, green circle). Both cystic locations correlated with the “hot spot” FDG uptake as shown in B and D 
(green arrows). 
 
recognized as a suspect for focal recurrence. 
Contrast-enhanced CT showed focal 
enhancement and, therefore, the patient 
underwent consecutive biopsy and 
cryosurgery. Histology confirmed the 
presence of viable RCC tissue. The post-LCA 
PET-CT of patient number 3 revealed 
irregular FDG accumulations in the ablation 
zone. However, contrast-enhanced CT 3 
months later showed no evidence of 
enhancement in the ablated tumor. In this 
case, the limited tumor dimension (19 mm 
diameter) possibly hampered the 
interpretation of the PET-CT findings.  
 
After LCA, in 4 more patients, metabolic 
activity was noticed at the rim of the 
ablation assessed by 18F-FDG PET-CT. In 
patient number 4, this was found in the 
peritumoral fat by the third consecutive 
PET-CT almost 3 years post-LCA, whereas 
previous scans showed no peripheral 
metabolic activity. Therefore, this must be 
considered a suspect for metastases. 
However, this is not confirmed by histology. 
In patient numbers 1, 2, and 5, the 
metabolic activity of the peripheral rim was 
encircling the metabolic inactive ablation 
zone as noticed in the first PET-CT following 
CA. This seems comparable to the literature 
where findings by CT and MRI of rim 
enhancement were noticed around the 
ablation zone in 17-30% of cases at 1 month 
after treatment (18-20). This periablational 
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enhancement is considered benign. It is 
suggested that this is a physiologic response 
to thermal injury, and it appears as a 
relatively concentric, symmetric, and 
uniform process with smooth inner margins 
(6). It seems that during the first month 
after ablation, this finding is of no 
consequence; however, if it were to occur 
later at follow-up, it could be interpreted as 
a sign of recurrence and will typically 
appear as irregular peripheral enhancement. 
The PET-CT findings of patient number 4 can 
possibly be interpreted as such. 
 
In this series, the PET-CT cross-sectional 
area stretched between the skull base and 
the groin. Therefore, using this technique, 
more than the local ablation site could be 
studied. The cross-sectional area of the 
thorax and abdomen, in combination with 
integrated method of imaging, enables us 
to locate metabolically active pulmonary, 
lymph node, or bone metastases. In patient 
number 7, 2 asymptomatic bone 
metastases were found this way. However, 
these lesions could also have been noticed 
during a cross-sectional contrast-enhanced 
CT of this area. 
 
The search for the best method to assess 
treatment success after cryosurgery for 
RMs remains subject to new investigations. 
However, in patients with relative or 
imperative contraindications for the use of 
contrast agents in CT or MRI, 18F-FDG 
PET-CT may be a reasonable alternative in 
the follow-up in CA of RMs. The total 
accumulated radiation dose of consecutive 
CT scans performed is considered 
negatively related to the follow-up of LCA. 
The radiation dose with PET-CT is lower 
compared to the radiation dose of a full 
diagnostic cross-sectional CT scan. The 
radiation dose of 185 MBq 18F-FDG is 
about 3-4 mSv. 
 
To our knowledge, this pilot study is the 
first to assess 18F-FDG PET-CT imaging, 
reviewing the spectrum of pre- and post-
ablation PET-CT findings, and to discuss its 
value in the follow-up of renal tumors 
treated with cryosurgery. However, this 
study has, as have most pilot studies, many 
limitations. Only a few patients, at different 
times after CA, were studied to examine the 
possibility of using 18F-FDG PET-CT imaging 
to characterize the lesion. No longitudinal 
data were collected, and no direct 
comparison with CT/MRI was intended. 
Furthermore, the majority of PET-CT 
findings are not confirmed by histology and, 
therefore, the accuracy could not be 
assessed. However, the results of this study 
show that 18F-FDG PET-CT can be used in 
the follow-up in patients with small RM that 
underwent CA. We assume that this justifies 
a larger prospective and comparative study 
to determine the exact value of this 
technique for assessing treatment success 
and detecting recurrent tumors after CA. 
 
Conclusion 
 
This experience with the 18F-FDG PET-CT 
for the follow-up of RM-CA showed that 
18F-FDG PET-CT imaging could be used to 
characterize CA tissue injury at different 
times after CA. A longitudinal prospective 
study, comparing 18F-FDG PET-CT imaging 
to CT/MRI and confirmed by histology, is 
needed to establish its exact value in the 
follow-up of RM-CA. 
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